journal article·2025-06

Multifunctional Small RNA Endogenous Modified Exosome‐Loaded Hydrogel Based on Photocrosslinking for Cartilage Repair

Junlei Lv, Hongyi Jiang, Zhiruo Qiu, Rongjie Liu, Yuqin Fang, Zeming Zhang, Miaolong Zhao, Xiang Li, Chao Lou, Haosheng Huang, Xiaolei Zhang, Wenhao Zheng, Liaojun Sun

Advanced Functional Materials· Volume 35· Issue 25
Publisher page

Abstract

Abstract Exosomes derived from bone marrow mesenchymal stem cells (BMSCs) hold significant potential in the treatment of osteoarthritis (OA). However, simple exosomes therapy often proves insufficiently effective and challenging to achieve optimal therapeutic outcome. Herein, an innovative injectable multifunctional composite hydrogel (Exo shEZH2 @HG) is composed of photocrosslinking partially modified hyaluronic acid with o ‐nitrobenzyl alcohol (HA‐NB), gelatin, and shRNA‐EZH2 endogenously modified exosomes (Exo shEZH2 ), designed for cartilage defects, which are a primary cause of early OA. It exhibits rapid and controllable photo‐induced gelation characteristics, resembling human cancellous bone compressive strength, and boasting excellent biocompatibility. In vitro studies indicate that Exo shEZH2 @HG slowly releases Exo shEZH2 , promoting the migration and infiltration of BMSCs into surrounding tissues. By inhibiting the overexpression of EZH2, Exo shEZH2 suppresses histone hypermethylation and the nuclear factor kappa‐B (NF‐κB) signaling pathway, thereby inhibiting inflammation and apoptosis in chondrocytes. Simultaneously, it promotes the regeneration of the extracellular matrix and the chondrogenic differentiation of BMSCs. Within a rat cartilage defect model, Exo shEZH2 @HG significantly facilitates the regeneration of cartilage tissue resembling hyaline cartilage in the defect area, preventing the progression of OA. In summary, this multifunctional composite hydrogel offers a promising approach for the treatment of cartilage defects and the prevention of OA through multiple synergistic effects.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Osteoarthritis Treatment and Mechanisms · Extracellular vesicles in disease · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopaedics The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University Key Laboratory of Orthopaedics of Zhejiang Provincial The Second Clinical Medical College of Wenzhou Medical University Wenzhou Zhejiang 325035 China

Wenzhou Medical University Wenzhou Zhejiang 325035 China

Funding

Wenzhou Municipal Science and Technology Bureau · Natural Science Foundation of Zhejiang Province

References (54)

Show source-provided references
1. 10.1097/BOR.000000000000047910.1097/BOR.0000000000000479 ↗
2. Liang L. · 2006
3. 10.1053/joca.1998.014010.1053/joca.1998.0140 ↗
4. 10.1016/j.matbio.2018.05.00810.1016/j.matbio.2018.05.008 ↗
5. 10.1016/j.mcna.2019.10.00710.1016/j.mcna.2019.10.007 ↗
6. 10.1126/science.284.5411.14310.1126/science.284.5411.143 ↗
7. 10.1016/j.biotechadv.2017.11.00910.1016/j.biotechadv.2017.11.009 ↗
8. 10.1016/bs.acc.2015.12.00510.1016/bs.acc.2015.12.005 ↗
9. 10.3389/fendo.2021.64623310.3389/fendo.2021.646233 ↗
10. 10.1186/s13287-017-0632-010.1186/s13287-017-0632-0 ↗
11. 10.1038/s41392-023-01382-y10.1038/s41392-023-01382-y ↗
12. 10.1016/j.ymthe.2018.04.02410.1016/j.ymthe.2018.04.024 ↗
13. 10.1016/j.ymthe.2017.03.03010.1016/j.ymthe.2017.03.030 ↗
14. 10.1038/aps.2013.16110.1038/aps.2013.161 ↗
15. 10.1186/s13045-020-00937-810.1186/s13045-020-00937-8 ↗
16. 10.1186/s40364-018-0122-210.1186/s40364-018-0122-2 ↗
17. 10.1038/srep2917610.1038/srep29176 ↗
18. 10.1016/j.ceb.2019.07.00810.1016/j.ceb.2019.07.008 ↗
19. 10.1016/j.diff.2016.02.00510.1016/j.diff.2016.02.005 ↗
20. 10.1186/s13287-018-0998-710.1186/s13287-018-0998-7 ↗
21. 10.1016/j.molcel.2011.08.01110.1016/j.molcel.2011.08.011 ↗
22. 10.1038/s41401-021-00837-810.1038/s41401-021-00837-8 ↗
23. Moore C. B. · Methods Mol. Biol. · 2010 · 629 · 141
24. 10.1038/nbt105210.1038/nbt1052 ↗
25. 10.3390/ijms2306311310.3390/ijms23063113 ↗
26. 10.1002/ctm2.87610.1002/ctm2.876 ↗
27. 10.1016/j.joca.2016.06.02210.1016/j.joca.2016.06.022 ↗
28. 10.1002/adfm.20130048310.1002/adfm.201300483 ↗
29. 10.1002/adfm.20160009210.1002/adfm.201600092 ↗
30. 10.1016/j.bioactmat.2022.07.01310.1016/j.bioactmat.2022.07.013 ↗
31. 10.1002/biot.20200009510.1002/biot.202000095 ↗
32. 10.1016/j.biotechadv.2017.05.00610.1016/j.biotechadv.2017.05.006 ↗
33. 10.1038/s41591-020-1013-210.1038/s41591-020-1013-2 ↗
34. 10.1016/j.copbio.2016.02.00810.1016/j.copbio.2016.02.008 ↗
35. 10.1002/adma.20150533610.1002/adma.201505336 ↗
36. 10.1126/sciadv.abg062810.1126/sciadv.abg0628 ↗
37. 10.1038/nm.403610.1038/nm.4036 ↗
38. 10.1038/s41467-019-13105-510.1038/s41467-019-13105-5 ↗
39. 10.1016/j.addr.2009.04.00410.1016/j.addr.2009.04.004 ↗
40. 10.1002/smll.20190004610.1002/smll.201900046 ↗
41. 10.1089/10763270041808310.1089/107632700418083 ↗
42. 10.1016/j.bioactmat.2021.09.01010.1016/j.bioactmat.2021.09.010 ↗
43. 10.1039/C7NR00352H10.1039/C7NR00352H ↗
44. 10.1016/j.bioactmat.2020.11.02010.1016/j.bioactmat.2020.11.020 ↗
45. 10.1016/j.biomaterials.2019.02.00610.1016/j.biomaterials.2019.02.006 ↗
46. 10.1093/jb/mvab00710.1093/jb/mvab007 ↗
47. 10.1016/j.lfs.2021.12025810.1016/j.lfs.2021.120258 ↗
48. 10.1038/s41419-019-1589-y10.1038/s41419-019-1589-y ↗
49. 10.1016/j.joca.2007.05.00510.1016/j.joca.2007.05.005 ↗
50. 10.1038/s41467-023-41594-y10.1038/s41467-023-41594-y ↗
51. 10.1016/j.bioactmat.2021.02.00510.1016/j.bioactmat.2021.02.005 ↗
52. 10.1021/acs.nanolett.0c0092910.1021/acs.nanolett.0c00929 ↗
53. 10.2106/00004623-200300002-0000710.2106/00004623-200300002-00007 ↗
54. 10.1016/j.joca.2005.07.01410.1016/j.joca.2005.07.014 ↗